mouse liver cancer cell line hepa1 6  (ATCC)

Journal: The Journal of Clinical Investigation

Article Title: THEMIS attenuates MASH by suppressing disease-associated hepatocyte induction and hepatocyte senescence in mice

doi: 10.1172/JCI199303

Figure Lengend Snippet: ( A ) Immunoblotting of total lysates from WT and Themis -KO livers. ( B ) Immunoblotting of total lysates from Themis Flox and HKO livers. ( C ) Immunoblotting of total lysates from mouse and human primary hepatocytes transduced with Ad-GFP or Ad-Themis. ( D ) Immunoblotting of Themis Flox and HKO mice primary hepatocytes stimulated with 100 ng/mL EGF at indicated time points. ( E ) RAS activity assessment of EGF-treated primary hepatocytes isolated from Flox and HKO mice fed MASH diet for 5 months. ( F and G ) Hepa1 cells overexpressing either GFP or Themis were treated with 50 nM doxorubicin (Dox) for 3 days. ( F ) SA-β-GAL staining of Hepa1 cells. ( G ) Immunoblotting of total lysates from Hepa1 cells. ( H ) Immunoblotting of total lysates. Hepa1 cells overexpressing either GFP or Themis were treated with 1 μM Dox for 2 hours, followed by 10 nM MEK inhibitor trametinib treatment for 3 days. Scale bars: 50 μm ( F ).

Article Snippet: Hepa1 cells (ATCC, CRL-1830) were transduced by adenovirus and then treated with Dox (Cayman, 15007), MEK inhibitor trametinib (MedChemExpress, HY-10999)], or the combination.

Techniques: Western Blot, Transduction, Activity Assay, Isolation, Staining

Journal: Frontiers in Immunology

Article Title: Targeting the TIGIT/CD155-induced metabolic checkpoint in NK cells restores anti-tumor immunity and suppresses hepatocellular carcinoma growth

doi: 10.3389/fimmu.2026.1790174

Figure Lengend Snippet: Validation of CD155-TIGIT signaling in SHP-2 recruitment and STAT3 pathway inhibition. (A) Schematic representation of the regulatory mechanism by which tumor cell CD155 modulates the SHP-2/STAT3 axis via TIGIT; (B) WB analysis of CD155 protein expression levels in Hepa1–6 cells; (C) Immunofluorescence staining showing SHP-2 expression and localization in co-cultured NK cells, scale bar: 25 µm; (D) Quantitative analysis of immunofluorescence signal intensity from panel C; (E) Co-IP assay demonstrating the interaction between SHP-2 and STAT3 in TIGIT-overexpressing NK cells; (F) Immunofluorescence colocalization analysis illustrating the distribution of SHP-2 and STAT3 in TIGIT-overexpressing NK cells, scale bar: 25 µm; (G) WB analysis of SHP-2, total STAT3, and its phosphorylated form p-STAT3 (Tyr705) protein levels in TIGIT or SHP-2-overexpressing NK cells. Experiments were conducted in triplicate. * indicates a statistically significant difference between groups, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The murine HCC cell line Hepa1-6 (ATCC ® CRL-1830TM) was maintained in high-glucose DMEM supplemented with 10% FBS (Gibco) and 1% penicillin–streptomycin (Gibco) at 37 °C in a humidified incubator containing 5% CO 2 .

Techniques: Biomarker Discovery, Inhibition, Expressing, Immunofluorescence, Staining, Cell Culture, Co-Immunoprecipitation Assay

Journal: Frontiers in Immunology

Article Title: Targeting the TIGIT/CD155-induced metabolic checkpoint in NK cells restores anti-tumor immunity and suppresses hepatocellular carcinoma growth

doi: 10.3389/fimmu.2026.1790174

Figure Lengend Snippet: Regulation of NK cell cytotoxicity against tumor cells via the TIGIT/STAT3/GLUT1 pathway. (A) Schematic diagram illustrating the modulation of NK cell anti-tumor activity through interventions on the TIGIT-STAT3-GLUT1 axis; (B, D) flow cytometry combined with CFSE/PI staining to assess the death rate of Hepa1–6 hepatocarcinoma cells, evaluating NK cell cytotoxicity; (C, E) LDH release assay measuring cell lysis levels in co-culture systems. Experiments were repeated three times. ** indicates p < 0.01 compared to the Control group, *** p < 0.001; # indicates p < 0.05 compared to the anti-TIGIT or IL-6+sh-NC groups.

Article Snippet: The murine HCC cell line Hepa1-6 (ATCC ® CRL-1830TM) was maintained in high-glucose DMEM supplemented with 10% FBS (Gibco) and 1% penicillin–streptomycin (Gibco) at 37 °C in a humidified incubator containing 5% CO 2 .

Techniques: Activity Assay, Flow Cytometry, Staining, Lactate Dehydrogenase Assay, Lysis, Co-Culture Assay, Control